AstraZeneca has started late-stage trials of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months.
from CBC | Health News https://ift.tt/3nZ1vOz
Aucun commentaire:
Enregistrer un commentaire